The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...

TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, today announced the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...

Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents This study reviewed all industry-sponsored phase I clinical trial protocols ...

“We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong. “This provides a clear clinical and ...

"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and ...